T
Thierry Berghmans
Researcher at Université libre de Bruxelles
Publications - 266
Citations - 7827
Thierry Berghmans is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 40, co-authored 252 publications receiving 7008 citations. Previous affiliations of Thierry Berghmans include Institut Jules Bordet.
Papers
More filters
Journal ArticleDOI
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
Céline Mascaux,N Iannino,Benoît Martin,Marianne Paesmans,Thierry Berghmans,Michèle Dusart,Annick Haller,Philippe Lothaire,Anne-Pascale Meert,Sébastien Noël,Jean-Jacques Lafitte,Jean-Paul Sculier +11 more
TL;DR: RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR.
Journal ArticleDOI
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
Arnaud Scherpereel,Philippe Astoul,Paul Baas,Thierry Berghmans,H Clayson,P. De Vuyst,Hendrik Dienemann,Françoise Galateau-Sallé,Christophe Hennequin,Gunnar Hillerdal,C. Le Pechoux,Luciano Mutti,Jean-Claude Pairon,R. Stahel,P. Van Houtte,J. Van Meerbeeck,David A. Waller,Walter Weder +17 more
TL;DR: It is emphasised that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre, and a three step pre-treatment assessment is proposed.
Journal ArticleDOI
Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
Thierry Berghmans,Michèle Dusart,Marianne Paesmans,Claude Hossein-Foucher,Irène Buvat,Catherine Castaigne,Arnaud Scherpereel,Céline Mascaux,Michel Moreau,Martine Roelandts,Stéphane Alard,Anne-Pascale Meert,Edward F. Patz,Jean-Jacques Lafitte,Jean-Paul Sculier +14 more
TL;DR: In this article, the authors conducted a systematic literature search and found 13 eligible studies dedicated to non-small cell lung cancer (NSCLC) and found that the primary tumor standardized uptake value (SUV) has a potential prognostic factor for survival.
Journal ArticleDOI
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.
E. Steels,Marianne Paesmans,Thierry Berghmans,Fabrice Branle,F. Lemaître,Céline Mascaux,Anne-Pascale Meert,Frédéric Vallot,Jean-Jacques Lafitte,Jean-Paul Sculier +9 more
TL;DR: Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44, and in each subgroup of nonssall cell Lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis.
Journal ArticleDOI
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
Anne-Pascale Meert,Benoît Martin,Philippe Delmotte,Thierry Berghmans,Jean-Jacques Lafitte,Céline Mascaux,Marianne Paesmans,Emmanuelle Steels,Jean-Marc Verdebout,Jean-Paul Sculier +9 more
TL;DR: A meta-analysis of the available survival results showed that EGF-R expression was not a statistically significant prognostic factor for survival in NSCLC, and Epidermal growth factor receptor might be a poor prognostic factors for survival for nonsmall-cell lung cancer.